Skip to content
›

Clinical Trial of Innovative TCM Drug Shenrong Granules Approved, Bringing Hope for ALS

Recently, Shenrong Granules, an innovative traditional Chinese medicine independently developed by Yiling Pharmaceutical, received the “Drug Clinical Trial Approval Notification” issued by the National Medical Products Administration, authorizing clinical trials of Shenrong Granules for patients with amyotrophic lateral sclerosis (ALS) diagnosed with the TCM syndrome of Governor Vessel (Du) deficiency according to syndrome differentiation.

Shenrong Granules is an innovative Chinese medicine developed under the guidance of the collateral-disease theory in TCM. This theory innovatively proposes a new academic perspective for treating ALS based on the extraordinary vessels and Governor Vessel, identifying the pathogenesis of ALS as deficiency of the Governor Vessel (Du) source. It establishes the treatment principle of supporting the source to counteract atrophy, nourishing the nutritive aspect to generate muscle, aimed at treating ALS patients with Governor Vessel deficiency syndrome, who present symptoms such as decreased muscle strength, muscle atrophy, muscle fasciculations, muscle stiffness or flaccidity, and unclear articulation.

Medical staff of the Amyotrophy Department at Hebei Yiling Hospital treating ALS patients

Shenrong Granules originated from an in-house preparation developed by the Amyotrophy Department of Hebei Yiling Hospital. Established in 1992, this department has treated over 100,000 patients from more than 30 countries and regions, achieving remarkable therapeutic outcomes. It has been designated as a key specialty by the National Administration of Traditional Chinese Medicine during the 10th, 11th, and 12th Five-Year Plans, and recognized as a “Demonstration Base for ALS Patient Assistance Services” by the Chinese Medical Doctor Association. Over more than 30 years, the department has developed 27 series of hospital preparations and conducted extensive clinical applications, accumulating rich clinical experience that laid a solid foundation for the development of Shenrong Granules.

ALS is a rare neurological disease that has attracted widespread attention in the medical community in recent years. It is included in the “First Batch of Rare Disease Catalog” jointly issued by the National Health Commission and four other ministries. It is estimated that there are over 40,000 patients in China. As a globally challenging disease, once clinical symptoms appear, patients typically survive only 3 to 5 years; only 20% survive beyond 5 years, and 10% survive beyond 10 years. ALS is classified by the World Health Organization alongside cancer, AIDS, leukemia, and rheumatoid arthritis as one of the five major incurable diseases. Currently, there is an extreme scarcity of effective drugs for ALS, and clinical treatment outcomes remain unsatisfactory.

Traditional Chinese medicine, as a treasure of Chinese traditional medicine, has a unique theoretical system and rich clinical experience. It offers distinct advantages in treating certain rare and refractory diseases. The approval of Shenrong Granules for clinical trials in ALS treatment is of great significance for promoting the application of TCM in ALS and is expected to provide patients with more effective treatment options.

This article is excerpted from Hebei News Network, dated 26 October 2023

Related reading